Clicky

Venus Medtech Hangzhou Inc(2500)

Description: Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.


Keywords: Medicine Hypertension Catheter Dysfunction Circulatory System Cardiac Surgery Surgeries Heart Valve Treatment Of Hypertension Valvular Heart Disease Aortic Valve Aortic Stenosis Cerebral Embolism Mitral Valve Valve Replacement Structural Heart Disease

Home Page: www.venusmedtech.com

No. 88, Jiangling Road
Hangzhou, 31005
China
Phone: 86 57 1877 72180


Officers

Name Title
Mr. Min Zeng Exec. Chairman
Mr. Zhenjun Zi Founder, GM & Exec. Director
Mr. Haiyue Ma CFO & Joint Company Sec.
Mr. Hou-Sen Lim MEng. COO, CTO & Exec. Director
Joyce Heo Director of Sales
Mr. Christopher Lee Richardson Head of U.S. Operations
Mr. Amir Gross Head of Venus Global Heart Valve Innovation Center
Shakeel Osman Sr. VP of Sales Europe
Mr. Wai Chiu Wong FCS Joint Company Sec.

Exchange: HK

Country: HK

Currency: Hong Kong Dollar (HK$)

Forward PE: 38.3142
Trailing PE: 0
Price-to-Book MRQ: 1.2063
Price-to-Sales TTM: 15.1735
IPO Date:
Fiscal Year End: December
Full Time Employees: 1039
Back to stocks